Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies.

With respect to pleural metastasis and mediastinum metastasis, OS trended shorter in patients with either the two metastases (Figure S5d-e and S5g-h), and both displayed a nonsignificant trend favoring atezolizumab relative to docetaxel (Figure S5f and S5i).

also in 5,406 other papers